Ondansetron - Model ODF - Prevention and Treatment of Chemo and Radiotherapy
From Prescription Healthcare Products
Ondansetron is indicated for the prevention and treatment of chemo- and radiotherapy induced nausea and vomiting (CINV and RINV), and for the prevention and treatment of post-operative nausea and vomiting (PONV). Has been Developed by APR in cooperation with MonoSol Rx for the USA market and Labtec TESA outside USA respectively. The ODF technology aims to get around administration problems of the drug and improve patient compliance.
-
Most popular related searches
Product Details
Film dissolves on the tongue within seconds (liquid not required). Gastrointestinal absorption comparable to immediate release, oral solid dosage forms.
Advantages of ODF:
- Ease of administration.Can be used in patients who have difficulties
- swallowing (elderly and young children).
- No liquid necessary.Film cannot be spat out.
- No risk of aspiration.Easy to take when out of home/travelling.
Ondansetron ODF (4 and 8 mg)
Ondansetron OroDispersible Film/Orally Disintegrating Film (ODF), designed to improve patient compliance, has a number of important advantages over conventional forms of ondansetron:
- Higher compliance compared with Zofran® tablets - swallowing is easy and water is not required.
- Higher compliance compared with Zofran® syrup - fluid intake not necessary, no strawberry taste in the mouth, improved dosing accuracy, and shorter handling times.
- Higher compliance compared with Zofran® OroDispersible tablets/orally disintegrating tablets (ODT) - easier to handle and store.
- The absence of aspartame in the formulation makes the product suitable for phenylketonuric patients, for whom the use of ondansetron Zofran® ODT is contraindicated.
Customer reviews
No reviews were found for Ondansetron - Model ODF - Prevention and Treatment of Chemo and Radiotherapy. Be the first to review!